Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric Open-label Randomized Controlled Study for Evaluating the Improvement of Endothelial Function in Stage II Peripheral Arterial Obstructive Disease Patients Treated With Sulodexide + Conventional Treatment {CT] Vs CT Alone

Trial Profile

A Multicentric Open-label Randomized Controlled Study for Evaluating the Improvement of Endothelial Function in Stage II Peripheral Arterial Obstructive Disease Patients Treated With Sulodexide + Conventional Treatment {CT] Vs CT Alone

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Sulodexide (Primary) ; HMG-CoA reductase inhibitors
  • Indications Arterial occlusive disorders
  • Focus Therapeutic Use
  • Acronyms AWAOMI2
  • Sponsors Alfa Wassermann Inc
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 25 Jun 2018 Planned initiation date changed from 15 Jan 2018 to 1 Sep 2018.
    • 19 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top